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Oral busulfan (BU) and intravenous cycloaphosphamide (CY) are standard conditionaing chemotherapeutic agents for allogeneic 
hematopoietic stem cell transplantation (HSCT) in 
thalassemic patients.1 Pharmacokinetic studies of oral 
BU demonstrate wide intera and intraindividual varia
ability in drug levels.2,3 The association between steadya
state plasma concentrations and areaaunderatheacurve 
(AUC) values for busulfan and the occurrence of graft 
failure, venoaocclusive disease (VOD), and early mora
tality have been reported.4a6 Graft rejection is a coma
mon adverse event found in thalassemic patients una
dergoing HSCT.1,7 The unpredictability of busulfan 
levels may further increase the high incidence of graft 
rejection known to occur in patients with thalassemia. 
The use of intravenous busulfan (IVBU) may overa
come the variability of plasma drug levels leading to 
increased favorable outcomes after HSCT. Andersson 
et al8 initially showed consistent AUCs of IVBU in 
adults with hematologic malignancies without increasa
ing side effects. Nguyen et al9 demonstrated that fixed 
dosing based on the actual weight of pediatric patients 
is well correlated with targeted AUC values. With these 
recommended dosages, IVBU can be successfully used 
without therapeutic drug monitoring.10 These data may 
enable clinicians to use IVBU conveniently in centers 
where pharmacokinetic studies can not be performed. 
Therefore, this study is intended to explore the efficacy 
and toxicity of IVBU as a part of a conditioning regia
men in thalassemic children undergoing HSC T witha
out drug monitoring. 
PATIENTS AND METHODS
We analyzed children diagnosed with homozygous 
betaathalassemia (β/β) and betaathalassemia/Hb E 
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(β/E) diseases undergoing HSCT during August 2006 
to September 2007. These patients had available 6/6 
HLAamatched related or unrelated donors. The paa
tients were assigned into Pesaro class 1, 2, or 3 as dea
scribed by Lucarelli et al.1
The conditioning regimen consisted of IVBU every 
6 hours on day –9 to –6 and intravenous CY 50 mg/
kg daily on day –5 to –2. The dosages of IVBU were 
adjusted based on body weight as follows: 1.0 mg/kg 
for <9 kg; 1.2 mg/kg for 9 to <16 kg; 1.1 mg/kg for 
16a23 kg; 0.95 mg/kg for >23 to 34 kg; 0.8 mg/kg 
for >34 kg. Oral phenytoin was given for seizure proa
phylaxis during day a10 to a6. Intravenous fludarabine 
and Fresenius antithymocyte globulin (ATG) were 
added for patients who received stem cells from an 
unrelated donor. Graft versus host disease (GVHD) 
prophylaxis consisted of intravenous cyclosporine A 
(CsA) 1.5 mg/kg every 12 hours starting day a 2 and 
intravenous methotrexate 5 mg/m2 on day +1, +3, +6, 
and +11. The intravenous CsA was changed to the 
oral form when the patients could tolerate oral media
cations. The CsA was administered until day +150, 
and then tapered and discontinued over 30 days, if 
the patient had no evidence of GVHD. The CsA level 
was maintained between 200 and 300 ng/mL. Daily 
intravenous GaCSF 5 mcg/kg was started on day +1 
and discontinued after neutrophil engraftment was 
documented. Acute GVHD grading and the severa
ity of chronic GVHD were analyzed as previously 
described.11,12 The severity of adverse side effects were 
graded according to the National Cancer Institute’s 
common toxicity criteria version 2.0.13 Hepatic VOD 
was diagnosed and classified into mild, moderate, and 
severe as described by McDonald et al.14
Neutrophil and platelet engraftment were defined as 
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an absolute neutrophil count (ANC) more than 500/
mm3 and platelet count more than 20 000/mm3 for 3 
consecutive days without platelet support, respectively. 
Chimerism status was studied by using fluorescence 
in situ hybridization of Y chromosome and short tana
dem repeat DNA study of peripheral blood leukocytes 
in sexamismatched and sexamatched donorarecipient 
pairs, respectively. The evaluation of donor chimerism 
was scheduled on day +28, +60, +120, +180 and at 
the end of the first year after transplantation. If there is 
clinical suspicion or laboratory evidence of graft rejeca
tion, chimerism status was checked more frequently.
RESULTS 
Ten patients with median age of 6 years (range, 1.9a8.4 
years) were treated with IVBUCY regimen during this 
study period (Table 1). The median followaup time was 
13 months (range 5a18) months. The patients received 
stem cells from sibling bone marrows (n=8), cord blood 
(n=1), and unrelated bone marrow (n=1). The mea
dian CD34+ cells in the grafts were 8.03×106 cells/kg 
(range, 0.32a14.76×106 cells/kg). The time to neutroa
phil engraftment range was 11 to 20 days (median 14.5 
days) and platelet engraftment range was 19 to 28 days 
(median 25 days). All the patients engrafted with full 
Table 1. Patient characteristics and results of treatment.
No. Age/Sex Diagnosis Ferritin (ng/mL) Class Stem cells
CD34+cells 
(106 cells/kg)
Engraftment (day) Follow up 
(months)Neutrophil Platelet
1. 7.8/F ß/E 2,130 2 BM 4.62 18 25 18
2. 5.5/M ß/ß 1,270 1 BM 8 13 25 17
3. 7.5/M ß/E 1,490 2 BM 4.22 14 27 16
4. 1.9/M ß/E 1,670 2 BM 8.05 11 27 14
5. 7.5/M ß/E 3,060 2 BM 8.7 12 29 14
6. 6.5/M ß/E 3,670 2 CB 0.32 18 21 12
7. 3.9/M ß/ ß 4,590 2 BM 14.76 16 25 9
8. 8.4/F ß/E 1,980 2 BM 14.65 15 25 8
9. 5.9/M ß/E 2,920 1 UBM 4.57 20 28 7
10. 5/M ß/E 1,480 2 BM 12 14 28 5
ß/ß: homozygous ß thalassemia disease; ß/E: ß thalassemia/HbE; BM: bone marrow; CB: cord blood; UBM: unrelated bone marrow
Table 2. Complications after stem cell transplantation.
Patient 
No. aGVHD cGHVD VOD Emesis Mucositis Enteritis Others
1. Grade I (skin) Limited - - Grade II Grade II BK cystitis
2. - - - - - Grade II -
3. - Limited Moderate - Grade I Grade II HT encephalopathy
4. Grade I (skin) - Moderate - - -
5. - - - Grade II - - -
6. - - - Grade II - - -
7. - - Moderate Grade II - - HT
8. - - Moderate Grade II - - -
9. - - Mild Grade II - - BK cystitis
10. - Limited - - - Grade III Adenovirus cystitis
 aGVHD: acute graft-versus-host-disesase; cGVHD: chronic graft-versus-host-disease; VOD: veno-occlusive diseas; HT: hypertension
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donor cells. No evidence of mixed chimerism or graft 
rejection was detected at the time of this report.
Mild mucositis (Grade IaII) was found in 2 patients 
only and Grade IIaIII enteritis in 4 patients. Mild and 
moderate hepatic VOD was diagnosed in 5 patients. 
The VOD resolved with fluid restriction, diuretics, and 
dopamine. Acute GVHD Grade I of skin occurred in 
2 patients and limited chronic GVHD in 3 patients. 
Patient no. 1 and 9 suffered from BK virus associated 
hemorrhagic cystitis on day +98 and +9, respectively. 
Patient (no. 10) had adenovirusaassociated hematuria 
on day +8. However, all three patients were successfully 
treated with aggressive hydration.
DISCUSSION
Pharmacokinetic studies of IVBU have shown the bena
efits over oral BU in terms of consistent plasma concena
trations and AUC levels as well as administrative cona
venience.8,9 Recently, Vassel et al10 have recommended 
fixed doses of IVBU according to body weight in pea
diatric age, and this resulted in satisfactory AUC levels 
even without drug monitoring. The authors performed 
a retrospective pharmacokinetic study in 55 patients 
with various diseases receiving autologous and allogea
neic HSCT. Over 80% of AUCs of the patients were 
within the therapeutic window. No patient experienced 
a subatherapeutic AUC, which is important for diseases 
with a high incidence of graft failure such as thalassea
mia. Therefore, IVBU with these recommended doses 
temped us to change the usage of oral to IV form. 
Our retrospective analysis of a homogenous group 
of thalassemic children confirmed the efficacy of using 
IVBU without the need for a pharmacokinetic study. All 
patients achieved full donor engraftment at 2 months afa
ter HSCT, which predicts the sustained longaterm stable 
chimerism in thalassemic patients.1 However, we have 
no patient with class 3 who is expected to have adverse 
outcome after HSCT.1 Therefore, the efficacy of IVBU 
in this group of patients needs further exploration. 
The transplant related toxicity after HSCT was mild 
and manageable. The common side effects of IVBU were 
stomatitis and enteritis, as reported in other studies.10,15 
The hepatic VOD was higher than in previous reports 
using IVBU in pediatric patients.10,15,16 This finding 
may need to be confirmed in a larger group of patients. 
Additionally, the difference of genetic polymorphism in 
glutatione Satransferase M1 among ethnicities may ina
fluence the risk of hepatic VOD after HSCT.17 
In conclusion, this study supports for the safety and 
efficacy of IVBU usage without drug monitoring in 
children. IVBU may reduce the risk of graft failure or 
mixed chimerism in thalassemic patients because of its 
consistent and predictable drug levels. A future study of 
IVBU in higharisk thalassemic patients is warranted.
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